<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03964506</url>
  </required_header>
  <id_info>
    <org_study_id>UBMT-19163</org_study_id>
    <nct_id>NCT03964506</nct_id>
  </id_info>
  <brief_title>Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant</brief_title>
  <official_title>A Pilot Study to Determine the Safety and Efficacy of Incorporating Hyperbaric Oxygen Therapy Into RIC Fludarabine and Melphalan and Allogeneic Hematopoietic Stem/Progenitor Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Omar Aljitawi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects with Acute Myeloblastic Leukemia (AML) and myelodysplastic syndrome (MDS) who are&#xD;
      considered eligible for reduced intensity conditioning allogeneic stem cell transplant by the&#xD;
      transplant team at WCI (Wilmot Cancer Institute)will be enrolled in the study. Patients will&#xD;
      receive Fludarabine starting day -6 and Melphalan on day -2 and HBO (Hyperbaric Oxygen)&#xD;
      therapy on day 0 of the transplant. Subjects will be followed for any toxicity related to&#xD;
      therapy. After neutrophil recovery is documented, the patients will be seen in clinic at&#xD;
      least weekly through day +100.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with Acute Myeloblastic Leukemia (AML) and myelodysplastic syndrome (MDS), who are&#xD;
      considered eligible for reduced intensity conditioning allogeneic stem cell transplant by the&#xD;
      transplant team at WCI(Wilmot Cancer Institute) will be enrolled in the study. Fludarabine&#xD;
      30mg/M2 will be given IV over 30-60 minutes on days -6 to -2 and Melphalan 140mg/M2 will be&#xD;
      given IV over 4-hours once on day -2 of the preparative regimen. Patients will receive HBO&#xD;
      therapy on day 0 of the transplant. The treatment consists of exposure to hyperbaric oxygen&#xD;
      at 2.5 atmospheric absolutes (ATA) for a total of 90 minutes after compression to 2.5&#xD;
      atmosphere absolutes (ATA) in a monoplace hyperbaric chamber (Model 3200/3200R, Sechrist&#xD;
      Industries, Inc., USA), breathing 100% oxygen. The subjects will be in the chamber for a&#xD;
      total of 120 minutes as approximately 10-15 minutes were spent during the compression and&#xD;
      decompression phases and subjects had 10 minute room air breaks every 30 minutes of&#xD;
      hyperbaric oxygen treatment. Patients will be seen daily until neutrophil count engraftment&#xD;
      is documented. After neutrophil recovery is documented, the patients will be seen in clinic&#xD;
      at least weekly through day +100. A final visit will be scheduled day +100. As part of&#xD;
      routine care, subjects will be followed daily or as directed by the treating physician until&#xD;
      neutrophil recovery, defined as three consecutive days of achieving a neutrophil count of&#xD;
      &gt;500/mm3. Laboratory testing will occur per institutional guidelines. Follow-up will continue&#xD;
      until Day +100. Donor chimerism and disease status will be determined by bone marrow biopsy&#xD;
      on Day +30 and day +100 post-transplant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immediate safety of hyperbaric oxygen therapy prior to allogeneic stem cell transplant</measure>
    <time_frame>24 hours</time_frame>
    <description>Treatment-limiting toxicities will be assessed 24-hours post-hyperbaric oxygen therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long term safety of hyperbaric oxygen therapy prior to allogeneic stem cell transplant</measure>
    <time_frame>100 days</time_frame>
    <description>Possible long-term effects of hyperbaric oxygen therapy treatment prior to allogeneic peripheral blood stem cell transplant will be assessed at day +100 post-transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil recovery</measure>
    <time_frame>100 days</time_frame>
    <description>based on the patient having achieved three consecutive days of Absolute Neutrophile Count (ANC) â‰¥ 500/microliter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete donor chimerism</measure>
    <time_frame>100 days</time_frame>
    <description>Bone marrow chimerism will be checked on day +30 and day +100 Bone Marrow (BM) samples according to our standard of care</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Hyperbaric Oxygen Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive HBO therapy one time on day 0 of the transplant. The treatment consists of exposure to hyperbaric oxygen at 2.5 atmospheric absolutes (ATA) for a total of 90 minutes after compression to 2.5 atmosphere absolutes (ATA) in a monoplace hyperbaric chamber (Model 3200/3200R, Sechrist Industries, Inc., USA), breathing 100% oxygen. The subjects will be in the chamber for a total of 120 minutes as approximately 10-15 minutes were spent during the compression and decompression phases and subjects had 10 minute room air breaks every 30 minutes of hyperbaric oxygen treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperbaric oxygen</intervention_name>
    <description>Reduced intensity conditioning Fludarabine and Melphalan with Hyperbaric Oxygen and Allogeneic Hematopoietic Stem Cell Transplant</description>
    <arm_group_label>Hyperbaric Oxygen Therapy</arm_group_label>
    <other_name>HBO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  subjects with acute Myeloid Leukemia (AML)&#xD;
&#xD;
          -  subjects with Myelodysplastic Syndrome&#xD;
&#xD;
          -  Karnofsky performance status (KPS) of greater than 70% Adequate Hepatic, renal,&#xD;
             cardiac and pulmonary function Women of child-bearing potential and men with partners&#xD;
             of child-bearing potential who agree to use adequate contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant or breastfeeding&#xD;
&#xD;
          -  severe chronic obstructive pulmonary disease requiring oxygen supplementation&#xD;
&#xD;
          -  history of spontaneous pneumothorax&#xD;
&#xD;
          -  prior chest surgery requiring thoracotomy or direct chest irradiation to the lungs&#xD;
&#xD;
          -  evidence of pneumothorax or significant pulmonary fibrosis on chest imaging within 60&#xD;
             days of transplant&#xD;
&#xD;
          -  active malignancy excluding Myeloid Leukemia (AML) or Myeldoysplastic Syndrome (MDS)&#xD;
&#xD;
          -  active ear/sinus infection&#xD;
&#xD;
          -  history of sinus or ear surgery, excluding myringotomy or ear tubes&#xD;
&#xD;
          -  no active tobacco use 72 hours prior to transplant&#xD;
&#xD;
          -  claustrophobia&#xD;
&#xD;
          -  history of seizures&#xD;
&#xD;
          -  asthma uncontrolled viral or bacterial infection at the time of study enrollment&#xD;
&#xD;
          -  active or recent (prior 6 months) invasive fungal infection without interdisciplinary&#xD;
             (ID) consult and approval.&#xD;
&#xD;
          -  intrathecal chemotherapy within 2 weeks of starting peparative regimen or cranial&#xD;
             irradiation within 4 weeks of starting preparative regimen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omar S Aljitawi, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Regulatory Coordinator</last_name>
    <phone>(585) 276-7078</phone>
    <email>Lisa_Metzger@URMC.Rochester.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wilmot Cancer Institute, University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omar Aljitawi</last_name>
    </contact>
    <contact_backup>
      <last_name>Lisa Metzger</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2019</study_first_posted>
  <last_update_submitted>December 14, 2020</last_update_submitted>
  <last_update_submitted_qc>December 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Omar Aljitawi</investigator_full_name>
    <investigator_title>Associate Professor of Hematology/Oncology</investigator_title>
  </responsible_party>
  <keyword>Allogeneic transplant</keyword>
  <keyword>Hyperbaric Oxygen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All individual participant data collected during the trial will be shared after deidentification, including dictionaries.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be available immediately following publication. No end date.</ipd_time_frame>
    <ipd_access_criteria>Anyone who wishes to access the data for any type of analyses.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

